BioLineRx announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the company’s clinical and medical functions. Her appointment is effective January 4, 2023. Dr. Rachmilewitz brings over 15 years of clinical development industry experience to the Company, including overseeing clinical development programs in oncology, immunology, and neurodegeneration. Previously, she was Senior Vice President of Clinical Development at VBL Therapeutics, where she led all aspects of the company’s immuno-oncology clinical trial programs and oversaw its clinical operations and medical affairs teams.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BLRX:
